Structured Administration and Supply Arrangement (SASA) – Issued for a Health Organisation

TITLE: Lidocaine for administration in the WA Rheumatic Heart Disease (RHD) Program

1. **Authority:**

   Issued by the Chief Executive Officer (CEO) of the WA Country Health Service (WACHS) under Part 6 of the Medicines and Poisons Regulations 2016.

2. **Scope and Criteria:**

   This SASA authorises the health professionals and actions specified in the table below.

Practitioner:	Nurses, Midwives and Aboriginal Health Practitioners working within their clinical scope of practice as defined by the WACHS Administration of Intramuscular Benzathine Benzylpenicillin G for Acute Rheumatic Fever and Rheumatic Heart Disease Policy.
Practice setting and/or service:	When employed by, or contracted to provide services for, WACHS to manage the public health program for acute rheumatic fever and rheumatic heart disease for patients on the Western Australian Rheumatic Heart Disease Register
Approved activity:	Administration
Approved medicine:	• Medicine Name: Lidocaine 1% (10 mg / mL) • Route: Intramuscular injection • Dose: 0.5mL lidocaine 1% with prescribed dose of benzathine benzylpenicillin prefilled syringe only or 0.25mL lidocaine 2% with prescribed dose of benzathine benzylpenicillin prefilled syringe only • Frequency: Every 21-28 days • Schedule 4
Approved indications (acute) or public health program:	To reduce pain associated with the administration of IM benzathine benzylpenicillin G prefilled syringe only in patients receiving this medication as part of the WA Rheumatic Heart Disease (RHD) Program
WACHS endorsed policy document	Administration must be used in accordance with the following WACHS endorsed policy documents: • Administration of Intramuscular Benzathine Benzylpenicillin G for Acute Rheumatic Fever and Rheumatic Heart Disease Policy

(s) e.g. clinical practice guidelines, procedure, policy	• WACHS SASA Intramuscular Benzathine Benzylpenicillin G (BPG) for Administration for the Rheumatic Heart Disease Program • ARF and RHD Guideline - RHD Menzies • PCH Benzanthine Benzylpencillin (Benzathine Penicillin G) Monograph – Paediatric • WACHS Medication Prescribing and Administration Policy

3. **General Conditions:**

The approved activity (administration and/or supply) of the identified medicine under this SASA is subject to the following conditions:

a. The health practitioner must only administer and/or supply the medicine per the above criteria within their clinical scope of practice.
b. Medicine selection, administration and/or supply and monitoring must be in accordance with WACHS endorsed clinical practice guidelines, procedure or policy identified in section 2 above.
c. If related to vaccinations, written or documented verbal consent must be obtained from the person, parent or guardian, before each instance of immunisation.
d. If related to Schedule 8 medicines, administration and/or supply must be in accordance with Part 11 of the Medicines and Poisons Regulations 2016.
e. Administration and/or supply must be recorded in the patient's health care record and include the minimum requirements outlined in regulation 143 of the Medicines and Poisons Regulations 2016. Record keeping for administration and/or supply is in accordance with Part 12 of the Medicines and Poisons Regulations 2016. S4 administration documentation must be kept for 2 years and S8 administration documentation must be kept for 5 years.
f. The medicines are procured by an authorised person or an appropriate Medicines and Poisons Permit holder. Procurement, storage, administration and supply is in accordance with Part 9 of the Medicines and Poisons Regulations 2016.

4. **Issued by:**

Name:	Rob Pulsford
Signature:	
Position:	WACHS A/Chief Executive
Date:	12 January 2026
Expiry:	16 November 2027
Issue number:	01_2025

Enquiries to: Rheumatic Heart Disease Program, Population Health
Email: RHD.Register2@health.wa.gov.au

5. **References:**

   a. Medicines and Poisons Regulations 2016
   b. ARF and RHD Guideline - RHD Menzies

Approval for Issuing (can be removed for publication to internet, original to be kept on record)			
WACHS Medicines and Therapeutics Committee			
Minute number:	5.1	Date endorsed:	17/11/2025
WACHS Senior Medical Practitioner			
Name and position:	Dr Helen Van Gessel, Executive Director Clinical Excellence		
Date approved:	05/01/2026	Signature: